A FIRST-IN-HUMAN TRIAL OF HSTC810 (ANTI-BTN1A1 AB), A NOVEL IMMUNE CHECKPOINT WITH A MUTUALLY EXCLUSIVE EXPRESSION WITH PD-1/PD-L1, IN PATIENTS WITH RELAPSED/REFRACTORY SOLID TUMORS

被引：1
作者：
Lee, Soohyeon [1 ]
Shin, Sangjoon [2 ]
Howie, Lynn [3 ]
Jung, Hyunjin [4 ]
Yoo, Steven [3 ,4 ]
Hong, David [5 ]
机构：
[1] Korea Univ, Anam Hosp, Seoul, South Korea
[2] Yonsei Canc Ctr, Seoul, South Korea
[3] STCube Pharmaceut Inc, Gaithersburg, MD USA
[4] STCube Inc, Seoul, South Korea
[5] MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0740
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
740
引用
收藏
页码：A773 / A773
页数：1
相关论文
共 50 条
  • [31] Characterization of the Expression of BTN1A1 exclusive to PD-L1/PD-1 axis in Small Cell Lung Cancer using Spatial Biology Approach
    Yoo, S. S.
    Jung, H.
    Kim, Y. -S.
    Wu, C.
    Park, A. H.
    Lee, S. H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S202 - S203
  • [32] Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone Tumors
    N. E. Kushlinskii
    A. A. Alferov
    Yu. S. Timofeev
    E. S. Gershtein
    I. V. Bulycheva
    A. V. Bondarev
    M. Yu. Shchupak
    N. Yu. Sokolov
    S. B. Polikarpova
    M. M. Efimova
    A. A. Dzampaev
    E. A. Sushentsov
    M. D. Aliev
    E. R. Musaev
    Bulletin of Experimental Biology and Medicine, 2020, 170 : 64 - 68
  • [33] Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone Tumors
    Kushlinskii, N. E.
    Alferov, A. A.
    Timofeev, Yu. S.
    Gershtein, E. S.
    Bulycheva, I. V.
    Bondarev, A. V.
    Shchupak, M. Yu.
    Sokolov, N. Yu.
    Polikarpova, S. B.
    Efimova, M. M.
    Dzampaev, A. A.
    Sushentsov, E. A.
    Aliev, M. D.
    Musaev, E. R.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 170 (01) : 64 - 68
  • [34] Immune checkpoint inhibitor (anti PD-1/PD-L1 antibody activity in dedifferentiated endometrial carcinoma.
    Ono, Ruriko
    Nakayama, Kentaro
    Itamochi, Hiroaki
    Nakamura, Kohei
    Sasamori, Hiroki
    Yamashita, Hitomi
    Ishibashi, Tomoka
    Ishikawa, Masako
    Ohnishi, Kaori
    Minamoto, Toshiko
    Iida, Kouji
    Ishikawa, Noriyoshi
    Otsuki, Yoshiro
    Kyo, Satoru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] IMMUNE PROFILING OF TESTICULAR GERM CELL TUMORS REVEALS HIGH EXPRESSION OF PD-L1 AND PD-1
    Taheri, Diana
    Rodriguez, Maria A. Mendoza
    Chaux, Alcides
    Drake, Charles
    Bivalacqua, Trinity J.
    Meeker, Alan
    Taube, Janis
    Gonzalez-Roibon, Nilda
    Nelson, William
    Yegnasubramanian, Sirinivasan
    Netto, George
    Haffner, Michael
    JOURNAL OF UROLOGY, 2016, 195 (04) : E841 - E842
  • [36] Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies)
    Ono, Ruriko
    Nakayama, Kentaro
    Nakamura, Kohei
    Yamashita, Hitomi
    Ishibashi, Tomoka
    Ishikawa, Masako
    Minamoto, Toshiko
    Razia, Sultana
    Ishikawa, Noriyoshi
    Otsuki, Yoshiro
    Nakayama, Satoru
    Onuma, Hideyuki
    Kurioka, Hiroko
    Kyo, Satoru
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (15)
  • [37] PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
    Gandini, Sara
    Massi, Daniela
    Mandala, Mario
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 : 88 - 98
  • [38] First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/ refractory advanced solid tumors: Interim data
    Ahn, Eugene R.
    Duvivier, Herbert Leon
    Rasco, Drew W.
    Rethy, Agnes
    Moore, Chris
    Yuet, Amy
    Hankins, Sandra R.
    Orlandella, Rachael
    Khanna, Swati
    Dekker, Joseph
    Georgy, Angela
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data
    Van Tine, Brian A.
    Ahn, Eugene
    Redman, Rebecca A.
    Barve, Minal A.
    Edenfield, William J.
    Peguero, Julio
    Villaflor, Victoria M.
    Rasco, Drew W.
    Powell, Steven F.
    Mamuye, Admasu T.
    Moore, Chris B.
    Pelham, Joshua M.
    Charoenthongtrakul, Soratree
    Spigel, David R.
    CANCER RESEARCH, 2024, 84 (07)
  • [40] Stomach cancer. clinical significance of the expression of key components of pd-1/pd-l1 immune checkpoint
    Kovaleva, Olga V.
    Podlesnaya, Polina A.
    Gratchev, Alexei N.
    Chang, Victor L.
    Ognerubov, Nikolai A.
    Kushlinskii, Nikolai E.
    Journal of Nonlinear and Variational Analysis, 2021, 5 (03): : 122 - 127
12345